These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492 [TBL] [Abstract][Full Text] [Related]
6. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. Gachard N; Salviat A; Boutet C; Arnoulet C; Durrieu F; Lenormand B; Leprêtre S; Olschwang S; Jardin F; Lafage-Pochitaloff M; Penther D; Sainty D; Reminieras L; Feuillard J; Béné MC; Haematologica; 2008 Feb; 93(2):215-23. PubMed ID: 18223290 [TBL] [Abstract][Full Text] [Related]
7. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status. Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689 [TBL] [Abstract][Full Text] [Related]
8. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Zanotti R; Ambrosetti A; Lestani M; Ghia P; Pattaro C; Remo A; Zanetti F; Stella S; Perbellini O; Prato G; Guida G; Caligaris-Cappio F; Menestrina F; Pizzolo G; Chilosi M Leukemia; 2007 Jan; 21(1):102-9. PubMed ID: 17082778 [TBL] [Abstract][Full Text] [Related]
9. Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia. Molica S; Digiesi G; Mirabelli R; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Morabito F; Neri A; Baldini L; Ferrarini M Eur J Haematol; 2009 Sep; 83(3):208-14. PubMed ID: 19459926 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. D'Arena G; Tarnani M; Rumi C; Vaisitti T; Aydin S; De Filippi R; Perrone F; Pinto A; Chiusolo P; Deaglio S; Malavasi F; Laurenti L Am J Hematol; 2007 Sep; 82(9):787-91. PubMed ID: 17534928 [TBL] [Abstract][Full Text] [Related]
11. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. Gentile M; Cutrona G; Mosca L; Matis S; Fabris S; Lionetti M; Ilariucci F; Zupo S; Musolino C; Levato L; Molica S; Di Raimondo F; Vincelli I; Di Rienzo N; Pesce EA; Angrilli F; Federico M; Neri A; Ferrarini M; Morabito F Am J Hematol; 2014 Jul; 89(7):743-50. PubMed ID: 24711230 [TBL] [Abstract][Full Text] [Related]
12. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482 [TBL] [Abstract][Full Text] [Related]
13. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Del Giudice I; Morilla A; Osuji N; Matutes E; Morilla R; Burford A; Maravelaki S; Owusu-Ankomah K; Swansbury J; A'Hern R; Brito-Babapulle V; Catovsky D Cancer; 2005 Nov; 104(10):2124-32. PubMed ID: 16211545 [TBL] [Abstract][Full Text] [Related]
15. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70). Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Del Principe MI; Del Poeta G; Venditti A; Buccisano F; Maurillo L; Marini R; Cox MC; Panetta P; Suppo G; Degan M; Bruno A; Gattei V; Amadori S Haematologica; 2004 Dec; 89(12):1468-75. PubMed ID: 15590397 [TBL] [Abstract][Full Text] [Related]
17. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121 [TBL] [Abstract][Full Text] [Related]
18. ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients. Zanotti R; Frattini F; Ghia P; Visco C; Zamò A; Perbellini O; Stella S; Facco M; Giaretta I; Chilosi M; Pizzolo G; Ambrosetti A Am J Hematol; 2010 Jul; 85(7):494-8. PubMed ID: 20575031 [TBL] [Abstract][Full Text] [Related]
19. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. Rassenti LZ; Huynh L; Toy TL; Chen L; Keating MJ; Gribben JG; Neuberg DS; Flinn IW; Rai KR; Byrd JC; Kay NE; Greaves A; Weiss A; Kipps TJ N Engl J Med; 2004 Aug; 351(9):893-901. PubMed ID: 15329427 [TBL] [Abstract][Full Text] [Related]
20. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis. Sheikholeslami MR; Jilani I; Keating M; Uyeji J; Chen K; Kantarjian H; O'Brien S; Giles F; Albitar M Cytometry B Clin Cytom; 2006 Jul; 70(4):270-5. PubMed ID: 16906585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]